Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Published:2014-04-18 Issue:7 Volume:13 Page:1826-1836
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Jiang Ning,Wang Dongsheng,Hu Zhongliang,Shin Hyung Ju C.,Qian Guoqing,Rahman Mohammad Aminur,Zhang Hongzheng,Amin A.R.M. Ruhul,Nannapaneni Sreenivas,Wang Xiaojing,Chen Zhengjia,Garcia Gabriela,MacBeath Gavin,Shin Dong M.,Khuri Fadlo R.,Ma Jun,Chen Zhuo G.,Saba Nabil F.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs;Cancer Drug Resistance;2024-04-29

2. NRG1 promotes tumorigenesis and metastasis and afatinib treatment efficiency is enhanced by NRG1 inhibition in esophageal squamous cell carcinoma;Biochemical Pharmacology;2023-12

3. NRG1 promotes tumorigenesis and metastasis and afatinib treatment efficiency is enhanced by NRG1 inhibition in esophageal squamous cell carcinoma;2023-07-25

4. Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer;Scientific Reports;2023-06-14

5. Pan-HER, an antibody mixture, simultaneously targeting EGFR, HER2, and HER3 effectively overcomes resistance to anti-EGFR antibodies;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023